Minimally invasive treatment as an alternative to bariatric surgery on the horizon
Westminster, CO (May 2, 2013) – Surefire Medical, Inc., the developer of a new class of infusion systems designed to maximize targeted delivery of embolization agents without reflux, today announced that the company’s Surefire Infusion System will be used in the development of the first clinically viable microcatheter-based, minimally invasive treatment for obesity as an alternative to bariatric surgery.
The Bariatric Arterial Embolization research at Johns Hopkins Medicine, led by principal investigators, Clifford Weiss, M.D., Assistant Professor of Radiology, and Dara Kraitchman, V.M.D, Ph. D,. FACC, Professor of Radiology, a porcine study, begins May 1, 2013 with a $1.3 million dollar grant from the National Institutes of Health (NIH).
The procedure precisely targets the fundus, the area of the stomach that produces ghrelin or the ‘hunger hormone.’ Multiple pharmacological attempts to curb ghrelin, a gastric hormone that stimulates hunger, have been largely unsuccessful.
The novel Surefire Infusion technology, with its unique expandable antireflux tip, was chosen for its ability to:
- Improve targeting
- Prevent reflux into healthy, non-target tissue
- Achieve deeper penetration of the X-Ray visible embolic beads (XEBs) developed for this study
“Bariatric Embolization will be the world’s first image-guided, minimally invasive procedure targeting obesity that could be a viable alternative to bariatric surgery,” said Aravind Arepally, M.D., Surefire Medical’s Chief Scientific Officer and former Clinical Director for the Center for Bioengineering Innovation and Design at Johns Hopkins. “In our prior work, which showed that this procedure may be as effective as bariatric surgery in curbing hunger, we realized that precise delivery into the gastric fundus was critical. The Surefire’s unique properties enable the more highly targeted, precise delivery vital for development of a new obesity treatment.”
About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip that collapses in forward flow and dynamically expands to the vessel wall in reverse flow in order to maximize targeted delivery, minimize reflux and reduce damage to healthy tissue.